Nanotech Delivery Request: A Corporate Presentation from Merck Research Laboratories
Representatives from Merck will make a special presentation to researchers and scientists in universities and companies at the Nanotech 2007 conference on May 23, 2007 at the Santa Clara Convention Center in California.
Merck recently acquired Sirna Therapeutics, a leader in efforts to create RNAi-based therapeutics that could significantly alter the treatment of disease. RNAi-based therapeutics selectively catalyze the destruction of the RNA transcribed from an individual gene enabling an novel approach to discovering drugs with the potential to produce highly specific, potent, and long-lasting effects.
The presentation will focus on areas Merck is especially interested in developing collaboration around enabling technologies that can be applied to the targeted delivery of siRNA particles in-vivo. Examples might include self-assembling polymer nanoparticles and cellular/organ-specific targeting strategies. Merck will also discuss their interest in novel assays to follow intracellular processing and trafficking of siRNA.
The presentation will be followed by a question and answer period and one-on-one meetings. To view the full program and register for the Nanotech Conference, please visit: www.nsti.org/Nanotech2007/.
